Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Edison Investment Research
$10.00
Provider: MarketLine (a Datamonitor Company)
$50.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Oxford Biomedica PLC Receives Agreement From FDA And ANSM To Resume Recruitment Into Ocular Clinical Trials


Thursday, 17 Oct 2013 02:05am EDT 

Oxford Biomedica PLC announced that it has received agreement from the US Food and Drug Administration (FDA) and the French regulatory agency, ANSM, to resume recruitment into the RetinoStat Phase I, StarGen Phase I/IIa and UshStat Phase I/IIa studies using the existing clinical trial material. 

Company Quote

4.025
0.025 +0.62%
9:20am EDT